DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,798 filers reported holding DANAHER CORPORATION in Q2 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $217,907,222 | +3.9% | 878,304 | +0.5% | 0.49% | +8.6% |
| Q2 2023 | $209,645,760 | +46.8% | 873,524 | +54.1% | 0.46% | +42.2% |
| Q1 2023 | $142,851,987 | -11.2% | 566,783 | -6.5% | 0.32% | -16.9% |
| Q4 2022 | $160,951,750 | -6.6% | 606,404 | -9.1% | 0.38% | -9.8% |
| Q3 2022 | $172,280,000 | -16.0% | 667,004 | -17.5% | 0.43% | -9.1% |
| Q2 2022 | $205,073,000 | -10.9% | 808,904 | +3.1% | 0.47% | +7.6% |
| Q1 2022 | $230,119,000 | -15.5% | 784,504 | -5.2% | 0.44% | -10.8% |
| Q4 2021 | $272,323,000 | +31.2% | 827,704 | +21.4% | 0.49% | +19.8% |
| Q3 2021 | $207,538,000 | +19.0% | 681,704 | +4.9% | 0.41% | +19.9% |
| Q2 2021 | $174,355,000 | +10.4% | 649,704 | -7.4% | 0.34% | +5.9% |
| Q1 2021 | $157,895,000 | -17.7% | 701,504 | -18.8% | 0.32% | -23.0% |
| Q4 2020 | $191,952,000 | +0.5% | 864,104 | -2.5% | 0.42% | -12.6% |
| Q3 2020 | $190,923,000 | +48.1% | 886,654 | +21.7% | 0.48% | +44.8% |
| Q2 2020 | $128,874,000 | +47.2% | 728,804 | +15.2% | 0.33% | +26.0% |
| Q1 2020 | $87,575,000 | -23.4% | 632,724 | -15.1% | 0.26% | -6.8% |
| Q4 2019 | $114,395,000 | +1.9% | 745,342 | -4.1% | 0.28% | +1.8% |
| Q3 2019 | $112,225,000 | +2.5% | 777,023 | +1.5% | 0.28% | +1.1% |
| Q2 2019 | $109,458,000 | +5.5% | 765,867 | -2.5% | 0.27% | +5.4% |
| Q1 2019 | $103,732,000 | +32.0% | 785,732 | +3.1% | 0.26% | +18.8% |
| Q4 2018 | $78,592,000 | -8.7% | 762,140 | -3.8% | 0.22% | +13.5% |
| Q3 2018 | $86,126,000 | +6.7% | 792,620 | -3.1% | 0.19% | +3.8% |
| Q2 2018 | $80,683,000 | +32.0% | 817,620 | +31.0% | 0.18% | +30.3% |
| Q1 2018 | $61,123,000 | +25.4% | 624,274 | +9.9% | 0.14% | +20.3% |
| Q3 2017 | $48,729,000 | -72.1% | 568,065 | -72.5% | 0.12% | -72.4% |
| Q2 2017 | $174,438,000 | +222.8% | 2,067,048 | +227.1% | 0.43% | +214.0% |
| Q1 2017 | $54,042,000 | -1.6% | 631,844 | -10.4% | 0.14% | -9.3% |
| Q4 2016 | $54,899,000 | +74.0% | 705,285 | +75.2% | 0.15% | +72.4% |
| Q3 2016 | $31,551,000 | -60.7% | 402,485 | -49.4% | 0.09% | -60.3% |
| Q2 2016 | $80,286,000 | +24.4% | 794,915 | +16.8% | 0.22% | +25.1% |
| Q1 2016 | $64,538,000 | -21.4% | 680,345 | -23.0% | 0.18% | -18.6% |
| Q4 2015 | $82,077,000 | -46.6% | 883,694 | -51.0% | 0.22% | -49.6% |
| Q3 2015 | $153,727,000 | +88.6% | 1,804,094 | +89.5% | 0.43% | +110.3% |
| Q2 2015 | $81,493,000 | -61.6% | 952,148 | -61.9% | 0.20% | -60.7% |
| Q1 2015 | $212,076,000 | +70.6% | 2,497,945 | +72.2% | 0.52% | +70.1% |
| Q4 2014 | $124,332,000 | +80.9% | 1,450,618 | +60.4% | 0.30% | +78.8% |
| Q3 2014 | $68,719,000 | -3.4% | 904,439 | +0.1% | 0.17% | -7.6% |
| Q2 2014 | $71,141,000 | -26.4% | 903,613 | -29.9% | 0.18% | -30.3% |
| Q1 2014 | $96,713,000 | -0.3% | 1,289,510 | +2.6% | 0.26% | +2.7% |
| Q4 2013 | $97,002,000 | -34.2% | 1,256,507 | -40.9% | 0.26% | -39.4% |
| Q3 2013 | $147,312,000 | -20.3% | 2,125,105 | -27.2% | 0.42% | -25.6% |
| Q2 2013 | $184,819,000 | +204.7% | 2,919,733 | +199.2% | 0.57% | +185.0% |
| Q1 2013 | $60,647,000 | – | 975,817 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |